Comparisons of native shiga toxins (Stxs) type 1 and 2 with chimeric toxins indicate that the source of the binding subunit dictates degree of toxicity

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Russo, Lisa M ^a   Melton Celsa, Angela R ^a   Smith, Michael J ^a   O'Brien, Alison D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; GLOBOTRIAOSYLCERAMIDE; SYNTAXIN; VEROTOXIN 1; VEROTOXIN 2; VIRULENCE FACTOR; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HEMORRHAGIC COLITIS; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MONOLAYER CULTURE; MOUSE; NONHUMAN; OPERON; PH; POLYMERASE CHAIN REACTION; RECEPTOR BINDING; VERO CELL LINE; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; ENZYME STABILITY; FECES; LD50; METABOLISM;

ANIMALS; BINDING SITES; CERCOPITHECUS AETHIOPS; ENZYME STABILITY; FECES; FEMALE; LETHAL DOSE 50; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SHIGA TOXIN 1; SHIGA TOXIN 2; VERO CELLS;

EID: 84899811668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093463     Document Type: Article

References (51)

1. Tilden J Jr, Young W, McNamara AM, Custer C, Boesel B, et al. (1996) A new route of transmission for Escherichia coli: infection from dry fermented salami. AmJ Public Health 86: 1142-1145. (Pubitemid 26271542)
2. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, et al. (2011) Foodborne illness acquired in the United States - major pathogens. EmergInfectDis 17: 7-15.
3. Griffin PM, Tauxe RV (1991) The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. EpidemiolRev 13: 60-98.
4. Armstrong GL, Hollingsworth J, Morris JG Jr (1996) Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. EpidemiolRev 18: 29-51. (Pubitemid 26303553)
5. Abdul-Raouf UM, Beuchat LR, Ammar MS (1993) Survival and growth of Escherichia coli O157:H7 in ground, roasted beef as affected by pH, acidulants, and temperature. ApplEnvironMicrobiol 59: 2364-2368. (Pubitemid 23222968)
6. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL (2005) Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. EmergInfect Dis 11: 603-609. (Pubitemid 40462912)
7. Abdul-Raouf UM, Beuchat LR, Ammar MS (1993) Survival and growth of Escherichia coli O157:H7 on salad vegetables. ApplEnvironMicrobiol 59: 1999-2006. (Pubitemid 23205780)
8. Boyce TG, Swerdlow DL, Griffin PM (1995) Escherichia coli O157:H7 and the hemolytic-uremic syndrome. NEnglJ Med 333: 364-368.
9. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, et al. (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli J InfectDis 151: 775-782. (Pubitemid 15094592)
10. Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of haemolyticuraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1: 619-620. (Pubitemid 13152343)
11. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ (2012) Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) 4: 1261-1287.
12. Melton-Celsa AR, O'Brien AD (1998) Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals. In: Kaper JB, O'Brien AD, editors. Escherichia coli O157:H7 and other Shiga toxin-producing E coli strains. Washington DC: ASM Press. pp. 121-128.
13. Fraser ME, Chernaia MM, Kozlov YV, James MN (1994) Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. NatStructBiol 1: 59-64. (Pubitemid 24974781)
14. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279: 27511-27517. (Pubitemid 38812591)
15. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, et al. (1987) Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro J BiolChem 262: 8834-8839.
16. Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, et al. (1992) Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358: 510-512.
17. Ogasawara T, Ito K, Igarashi K, Yutsudo T, Nakabayashi N, et al. (1988) Inhibition of protein synthesis by a Vero toxin (VT2 or Shiga-like toxin II) produced by Escherichia coli O157:H7 at the level of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes. MicrobPathog 4: 127-135.
18. Saxena SK, O'Brien AD, Ackerman EJ (1989) Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J BiolChem 264: 596-601. (Pubitemid 19027648)
19. Orth D, Grif K, Khan AB, Naim A, Dierich MP, et al. (2007) The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 59: 235-242. (Pubitemid 350016692)
20. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, et al. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J ClinMicrobiol 37: 497-503. (Pubitemid 29091254)
21. Ito H, Terai A, Kurazono H, Takeda Y, Nishibuchi M (1990) Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. MicrobPathog 8: 47-60. (Pubitemid 20222891)
22. Kleanthous H, Smith HR, Scotland SM, Gross RJ, Rowe B, et al. (1990) Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects. Arch Dis Child 65: 722-727. (Pubitemid 20220429)
23. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, et al. (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J InfectDis 160: 994-998. (Pubitemid 20002767)
24. Neupane M, Abu-Ali GS, Mitra A, Lacher DW, Manning SD, et al. (2011) Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease. MicrobPathog 51: 466-470.
25. Head SC, Karmali MA, Lingwood CA (1991) Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J BiolChem 266: 3617-3621. (Pubitemid 21909257)
26. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. InfectImmun 61: 3392-3402. (Pubitemid 23223431)
27. Head SC, Karmali MA, Lingwood CA (1991) Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 266: 3617-3621. (Pubitemid 21909257)
28. Zumbrun SD, Hanson L, Sinclair JF, Freedy J, Melton-Celsa AR, et al. (2010) Human Intestinal Tissue and Cultured Colonic Cells Contain Globotriaosylceramide Synthase mRNA and the Alternate Shiga Toxin Receptor, Globotetraosylceramide. InfectImmun 78: 4488-4499.
29. Lingwood CA (1996) Role of verotoxin receptors in pathogenesis. Trends Microbiol 4: 147-153.
30. Lindgren SW, Melton AR, O'Brien AD (1993) Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. InfectImmun 61: 3832-3842. (Pubitemid 23260057)
31. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O'Brien AD (1990) Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. InfectImmun 58: 3959-3965.
32. Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA (2002) Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 62: 832-845. (Pubitemid 35316712)
33. Ito H, Yutsudo T, Hirayama T, Takeda Y (1988) Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from Escherichia coli O157:H7. MicrobPathog 5: 189-195. (Pubitemid 18263593)
34. Weinstein DL, Jackson MP, Perera LP, Holmes RK, O'Brien AD (1989) In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga- like toxins and role of the B subunit in localization and cytotoxic activity. InfectImmun 57: 3743-3750. (Pubitemid 20001242)
35. Shimizu T, Sato T, Kawakami S, Ohta T, Noda M, et al. (2007) Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity. MicrobPathog 43: 88-95. (Pubitemid 46991195)
36. Austin PR, Jablonski PE, Bohach GA, Dunker AK, Hovde CJ (1994) Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity. InfectImmun 62: 1768-1775.
37. National Institutes of H (1985) Guide for the care and use of laboratory animals. National Institutes of Health publication no. 85-23; National Institutes of H, editor. Bethesda, Md: National Institutes of Health.
38. Tesh VL, Samuel JE, Perera LP, Sharefkin JB, O'Brien AD (1991) Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J InfectDis 164: 344-352.
39. Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O'Brien AD (2006) Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24: 4122-4129.
40. Russo LM, Melton-Celsa AR, Smith MA, Smith MJ, O'Brien A D (2013) Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10. Infect Immun.
41. Strockbine NA, Marques LR, Holmes RK, O'Brien AD (1985) Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli Infect Immun 50: 695-700. (Pubitemid 16216861)
42. Downes FP, Barrett TJ, Green JH, Aloisio CH, Spika JS, et al. (1988) Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. InfectImmun 56: 1926-1933.
43. Gentry MK, Dalrymple JM (1980) Quantitative microtiter cytotoxicity assay for Shigella toxin. J ClinMicrobiol 12: 361-366. (Pubitemid 10054028)
44. Schmitt CK, McKee ML, O'Brien AD (1991) Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. InfectImmun 59: 1065-1073.
45. Hurley BP, Jacewicz M, Thorpe CM, Lincicome LL, King AJ, et al. (1999) Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. InfectImmun 67: 6670-6677.
46. Chark D, Nutikka A, Trusevych N, Kuzmina J, Lingwood C (2004) Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. EurJ Biochem 271: 405-417. (Pubitemid 38130468)
47. Staples M, Jennison AV, Graham RM, Smith HV (2012) Evaluation of the Meridian Premier EHEC assay as an indicator of Shiga toxin presence in direct faecal specimens DiagnMicrobiolInfectDis.
48. Jemal C, Haddad JE, Begum D, Jackson MP (1995) Analysis of Shiga toxin subunit association by using hybrid A polypeptides and site-specific mutagenesis. J Bacteriol 177: 3128-3132.
49. Marcato P, Vander HK, Mulvey GL, Armstrong GD (2003) Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer. Infect Immun 71: 6075-6078. (Pubitemid 37205665)
50. Kitova EN, Mulvey GL, Dingle T, Sinelnikov I, Wee S, et al. (2009) Assembly and stability of the shiga toxins investigated by electrospray ionization mass spectrometry. Biochemistry 48: 5365-5374.
51. Louise CB, Obrig TG (1995) Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J InfectDis 172: 1397-1401.